Pfizer says Merck KGaA Ab pact will speed discoveries in 2015
Pfizer says its antibody alliance with Merck KGaA will let it fast-track development of combination biologics in 2015.
Pfizer says its antibody alliance with Merck KGaA will let it fast-track development of combination biologics in 2015.
Researchers have used shear stress to repair misfolded proteins in an approach that could help biopharmaceutical firms bypass expensive refolding techniques and time-consuming cell line optimization.
Amgen has benefited from enhanced regulatory discussions surrounding biosimilars, the firm says, as it develops a pipeline of nine products alongside its own biologics.